<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39391091</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1759-720X</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Therapeutic advances in musculoskeletal disease</Title><ISOAbbreviation>Ther Adv Musculoskelet Dis</ISOAbbreviation></Journal><ArticleTitle>The incidence of vasculitides in Israel from 2007 to 2021 and during the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>1759720X241274032</StartPage><MedlinePgn>1759720X241274032</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1759720X241274032</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/1759720X241274032</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The incidence of various types of vasculitis conditions over time, specifically during coronavirus disease 2019 (COVID-19), is unknown.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">We aimed to assess recent trends in vasculitides and the effect of the COVID-19 pandemic on these trends.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">We conducted a retrospective analysis of Israel's largest Health Maintenance Organization, which covers over 4.7 million patients and represents 55% of the country.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We calculated the age- and sex-adjusted incidence of giant cell arteritis (GCA), Takayasu, ANCA-associated vasculitis (AAV), IgA vasculitis, cryoglobulinemia, and Behcet's disease (BD) during 2007-2021. We analyzed associations of COVID-19 with the incidence of each of the examined conditions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">During 2007-2021, the adjusted annual incidence decreased from 7.9 (95% confidence interval (CI) 3.5-17.9) to 1.5 (95% CI 0.7-3.6) per 100,000 for GCA, from 5.2 (95% CI 2.7-11.1) to 1.5 (95% CI 0.7-3.3) per million for IgA vasculitis, and from 6.3 (95% CI 3.0-13.5) to 1.0 (0.5-2.5) per 100,000 for BD. The relative risks for these conditions decreased: 0.92 (95% CI 0.91-0.93), 0.93 (95% CI 0.89-0.98), and 0.90 (95% CI 0.85-0.94), respectively. The incidences of Takayasu, AAV, and cryoglobulinemia remained unchanged. The COVID-19 pandemic was not associated with changes in the incidence of any examined vasculitides.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The incidences of GCA, IgA vasculitis, and BD decreased substantially in Israel during 15 years and were unaffected by the COVID-19 pandemic. Future studies should focus on possible environmental contributions to these findings.</AbstractText><CopyrightInformation>© The Author(s), 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeller</LastName><ForeName>Lior</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rheumatology Disease Unit, Soroka University Medical Center, Beer Sheva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben David</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Rheumatology Disease Unit, Soroka University Medical Center, Beer Sheva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novack</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abuhasira</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Rheumatology Disease Unit, Soroka University Medical Center, Beer Sheva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abu-Shakra</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rheumatology Disease Unit, Soroka University Medical Center, Beer Sheva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miskin</LastName><ForeName>Yuval</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagy</LastName><ForeName>Iftach</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-2720-9934</Identifier><AffiliationInfo><Affiliation>Rheumatology Disease Unit, Soroka University Medical Center, Rager Bvd., Beer Sheva 84101, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Musculoskelet Dis</MedlineTA><NlmUniqueID>101517322</NlmUniqueID><ISSNLinking>1759-720X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ANCA-associated vasculitis</Keyword><Keyword MajorTopicYN="N">IgA vasculitis</Keyword><Keyword MajorTopicYN="N">giant cell arteritis</Keyword><Keyword MajorTopicYN="N">vasculitis</Keyword></KeywordList><CoiStatement>The authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39391091</ArticleId><ArticleId IdType="pmc">PMC11465294</ArticleId><ArticleId IdType="doi">10.1177/1759720X241274032</ArticleId><ArticleId IdType="pii">10.1177_1759720X241274032</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jennette JC, Falk RJ, Bacon PA, et al.. 2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013; 65(1): 1–11.</Citation><ArticleIdList><ArticleId IdType="pubmed">23045170</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatis P, Turkiewicz A, Englund M, et al.. Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate. Rheumatology 2021; 61(1): 146–153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8742826</ArticleId><ArticleId IdType="pubmed">33742665</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsen AT, Karlsen C, Bakland G, et al.. Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. Rheumatology 2020; 59(9): 2316–2324.</Citation><ArticleIdList><ArticleId IdType="pubmed">31859355</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce FA, Lanyon PC, Grainge MJ, et al.. Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. Rheumatology 2016; 55(9): 1656–1663.</Citation><ArticleIdList><ArticleId IdType="pubmed">27274096</ArticleId></ArticleIdList></Reference><Reference><Citation>Berti A, Cornec D, Crowson CS, et al.. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota: a twenty-year US population-based study. Arthritis Rheum 2017; 69(12): 2338–2350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5711593</ArticleId><ArticleId IdType="pubmed">28881446</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts RA, Hatemi G, Burns JC, et al.. Global epidemiology of vasculitis. Nat Rev Rheumatol 2022; 18(1): 22–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8633913</ArticleId><ArticleId IdType="pubmed">34853411</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrà A, Verdelli A, Mariotti EB, et al.. Cutaneous vasculitis: lessons from COVID-19 and COVID-19 vaccination. Front Med (Lausanne) 2022; 9: 1013846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9780506</ArticleId><ArticleId IdType="pubmed">36569148</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong K, Farooq Alam Shah MU, Khurshid M, et al.. COVID-19 associated vasculitis: a systematic review of case reports and case series. Ann Med Surg 2022; 74: 103249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754903</ArticleId><ArticleId IdType="pubmed">35039779</ArticleId></ArticleIdList></Reference><Reference><Citation>David R, Hanna P, Lee K, et al.. Relapsed ANCA associated vasculitis following Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients. Nephrol Carlton Vic 2022; 27(1): 109–110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646290</ArticleId><ArticleId IdType="pubmed">34755433</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramdani Y, Bettuzzi T, Bouznad A, et al.. IgA vasculitis following COVID-19 vaccination: a French multicenter case series including 12 patients. J Rheumatol 2023; 50(2): 252–257.</Citation><ArticleIdList><ArticleId IdType="pubmed">36319000</ArticleId></ArticleIdList></Reference><Reference><Citation>Vornicu A, Berechet A, Frăͣilă G, et al.. Relapse of cryoglobulinemic vasculitis with new-onset severe renal involvement in two patients following mRNA COVID-19 vaccination. Medicine (Baltimore) 2022; 101(23): e29431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9276277</ArticleId><ArticleId IdType="pubmed">35687780</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ministry of Health. Collection of statistical data—20 years of the National Health Insurance Law, https://www.health.gov.il/English/News_and_Events/Spokespersons_Messages/Pages/03062015_2.aspx#.%20Published%202015.%20Accessed%20October%2015,%202022 (2015, accessed 20 September 2023).</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al.. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335(7624): 806–808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder L, Cohen AD, Feldhamer I, et al.. The epidemiology of psoriatic arthritis in Israel—a population-based study. Arthritis Res Ther 2018; 20(1): 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5795280</ArticleId><ArticleId IdType="pubmed">29329596</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesher G, Ben-Chetrit E, Mazal B, et al.. The incidence of primary systemic vasculitis in Jerusalem: a 20-year hospital-based retrospective study. J Rheumatol 2016; 43(6): 1072–1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">27084915</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhtyar CB, Beadsmoore C, Coath FL, et al.. Incidence of primary large vessel vasculitis in Norfolk, UK from 2011 to 2020. Ann Rheum Dis 2023; 82(10): 1341–1347.</Citation><ArticleIdList><ArticleId IdType="pubmed">37399329</ArticleId></ArticleIdList></Reference><Reference><Citation>Brekke LK, Diamantopoulos AP, Fevang BT, et al.. Incidence of giant cell arteritis in Western Norway 1972–2012: a retrospective cohort study. Arthritis Res Ther 2017; 19(1): 278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732381</ArticleId><ArticleId IdType="pubmed">29246164</ArticleId></ArticleIdList></Reference><Reference><Citation>Barra L, Pope JE, Pequeno P, et al.. Incidence and prevalence of giant cell arteritis in Ontario, Canada. Rheumatology 2020; 59(11): 3250–3258.</Citation><ArticleIdList><ArticleId IdType="pubmed">32249899</ArticleId></ArticleIdList></Reference><Reference><Citation>Vladimir D. Aliyah from the Former Soviet Union: contribution to the national security balance. Jerusalem, Israel: The Israeli Ministry of Immigrant Absorptions, 2010.</Citation></Reference><Reference><Citation>Catanoso M, Macchioni P, Boiardi L, et al.. Incidence, prevalence, and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year period. Arthritis Care Res 2017; 69(3): 430–438.</Citation><ArticleIdList><ArticleId IdType="pubmed">27214746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizuka DK, Katayama K, Ohira Y. Giant cell arteritis presenting with chronic cough and headache after BNT162b2 mRNA COVID-19 vaccination. QJM Int J Med 2022; 115(9): 621–622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384497</ArticleId><ArticleId IdType="pubmed">35818985</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Torres V, Soriano V, Calderón-Parra J, et al.. Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: a nationwide population study. Autoimmun Rev 2023; 22(6): 103341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10103528</ArticleId><ArticleId IdType="pubmed">37062441</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, et al.. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Care Res 2003; 49(3): 388–393.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794795</ArticleId></ArticleIdList></Reference><Reference><Citation>Hočevar A, Rotar Z, Ostrovršnik J, et al.. Incidence of IgA vasculitis in the adult Slovenian population. Br J Dermatol 2014; 171(3): 524–527.</Citation><ArticleIdList><ArticleId IdType="pubmed">24601900</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisons V, Ramdani Y, Hankard A, et al.. New insights into epidemiological data and impact of the COVID-19 pandemic on IgA vasculitis in children and adults: a French nationwide cohort. Rheumatol Int 2023; 43(10): 1791–1798.</Citation><ArticleIdList><ArticleId IdType="pubmed">37438546</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramdani Y, Largeau B, Jonville-Bera AP, et al.. COVID-19 vaccination as a trigger of IgA vasculitis: a global pharmacovigilance study. J Rheumatol 2023; 50(4): 564–567.</Citation><ArticleIdList><ArticleId IdType="pubmed">36379583</ArticleId></ArticleIdList></Reference><Reference><Citation>Khairallah M, Accorinti M, Muccioli C, et al.. Epidemiology of Behçet disease. Ocul Immunol Inflamm 2012; 20(5): 324–335.</Citation><ArticleIdList><ArticleId IdType="pubmed">23030353</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun JB, Kim HJ, Kazmi SZ, et al.. Significant decline in the incidence of Behçet’s disease in South Korea: a nationwide population-based study (2004–2017). Arthritis Care Res 2021; 73(11): 1689–1696.</Citation><ArticleIdList><ArticleId IdType="pubmed">32770715</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammad A, Mandl T, Sturfelt G, et al.. Incidence, prevalence and clinical characteristics of Behçet’s disease in southern Sweden. Rheumatology 2013; 52(2): 304–310.</Citation><ArticleIdList><ArticleId IdType="pubmed">23012468</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanecki K, Nitsch-Osuch A, Goryński P, et al.. Behçet’s disease: rare systemic vasculitis in Poland. Pol Arch Intern Med 2017; 127(10): 652–656.</Citation><ArticleIdList><ArticleId IdType="pubmed">28837541</ArticleId></ArticleIdList></Reference><Reference><Citation>Seirafianpour F, Pourriyahi H, Gholizadeh Mesgarha M, et al.. A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. Dermatol Ther 2022; 35(6): e15461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111423</ArticleId><ArticleId IdType="pubmed">35316551</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang R, Chen TYT, Wang SI, et al.. Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. EClinicalMedicine 2023; 56: 101783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830133</ArticleId><ArticleId IdType="pubmed">36643619</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorpe CT, Thorpe JM, Jiang T, et al.. Healthcare utilization and expenditures for United States Medicare beneficiaries with systemic vasculitis. Semin Arthritis Rheum 2018; 47(4): 507–519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743622</ArticleId><ArticleId IdType="pubmed">28918956</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace ZS, Yun H, Curtis JR, et al.. ANCA-associated vasculitis management in the United States: data from the Rheumatology Informatics System for Effectiveness (RISE) registry. J Rheumatol 2021; 48(7): 1060–1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">33526622</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard L, Polcwiartek C, Nelveg-Kristensen KE, et al.. Increased risk of cardiovascular disease preceding diagnosis of incident ANCA-associated vasculitis: a Danish nationwide study. Rheumatology 2024; 63(5): 1313–1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">37481712</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause I, Yankevich A, Fraser A, et al.. Prevalence and clinical aspects of Behcet’s disease in the north of Israel. Clin Rheumatol 2007; 26(4): 555–560.</Citation><ArticleIdList><ArticleId IdType="pubmed">16897122</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaber L, Milo G, Halpern GJ, et al.. Prevalence of Behçet’s disease in an Arab community in Israel. Ann Rheum Dis 2002; 61(4): 365–366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1754053</ArticleId><ArticleId IdType="pubmed">11874845</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>